The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | The impact of next-generation BTK inhibitors on the lymphoma treatment landscape
Julie Vose, MD, University of Nebraska Medical Center, Omaha, NE, briefly discusses the positive impact next-generation BTK inhibitors (BTKis) will have on the treatment of patients with lymphoma due to their improved toxicity profile and tolerability, and equal or greater efficacy when compared to prior generations. There is also potential for combining these BTKis with additional agents to improve patient outcomes. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Abbvie, AstraZeneca, Genmab, MEI Pharma, Genentech, Seattle Genetics, Lilly
